C
Cytek Biosciences, Inc. (CTKB)
NMS – Real Time Price. Currency in USD
4.48
+0.01 (0.22%)
At close: Jun 26, 2026, 4:00 PM EDT
4.74
+0.26 (5.81%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
4.48
+0.01 (0.22%)
At close: Jun 26, 2026, 4:00 PM EDT
4.74
+0.26 (5.81%)
After-hours: Jun 26, 2026, 7:53 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $65.7M significantly exceed its total debt $36.3M, ensuring strong financial flexibility
Total current assets $379.3M exceed Total current liabilities $80.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (1.1), showcasing prudent financial management
Interest coverage ratio (-70.5x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$4.9M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.69 | 3.40 | 10 | |
| Quick ratio | 4.07 | 2.52 | 10 | |
| Debt to Equity | 0.11 | 1.11 | 9.0 | |
| Debt to Assets | 0.08 | 1.58 | 9.0 | |
| Interest coverage | -70.47 | 4.33 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 164M | 193M | 200M | 201M | 204M |
| Gross Profit | 102M | 109M | 111M | 104M | 106M |
| Operating Income | -1M | -26M | -23M | -40M | -44M |
| Net Income | 3M | -12M | -6M | -67M | -74M |
| EBITDA | 4M | -17M | -13M | -28M | -32M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 6.6 | -112.5 | 3.0 |
| Next quarter | 5.49 | -1527.55 | 3.0 |
| Current year | 3.64 | 32.69 | 7.0 |
| Next year | 6.63 | 23.81 | 7.5 |
| Weighted average score | 5.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -28.97 | 57.2 | 55.88 | -176.74 | 5.5 |
| Y/Y | 6.46 | -65.45 | -66.66 | -403.48 | 2.0 |
| 3y average | 7.35 | -508.8 | 28.54 | 1105.07 | 6.5 |
| 5y average | 17.61 | -125.47 | 1.96 | -1029.11 | 3.5 |
| Weighted average score | 4.4 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |